During the 2010
influenza season in Australia, administration of a 2010 Southern Hemisphere seasonal
influenza trivalent
inactivated vaccine (TIV) (Fluvax Junior and Fluvax) manufactured by CSL
Biotherapies was associated with increased frequency of
fever and
febrile seizures in children aged 6 months through 4 years. Postmarketing surveillance indicated increased reports of
fever in children aged 5-8 years after vaccination with Fluvax compared to previous seasons. An antigenically equivalent 2010-11 Northern Hemisphere seasonal
influenza TIV (
Afluria) manufactured by CSL
Biotherapies is approved by the Food and Drug Administration (FDA) for persons aged >or=6 months in the United States. Prescribing information for the 2010-11
Afluria formulation includes a warning that "Administration of CSL's Southern Hemisphere
influenza vaccine has been associated with increased postmarketing reports of
fever and
febrile seizures in children predominantly below the age of 5 years as compared to previous years". In the United States, annual
influenza vaccination is recommended for all persons aged >or=6 months. On August 5, 2010, the Advisory Committee on Immunization Practices (ACIP) recommended that the 2010-11
Afluria vaccine not be administered to children aged 6 months through 8 years. Other age-appropriate, licensed seasonal
influenza vaccine formulations should be used for prevention of
influenza in these children. If no other age-appropriate, licensed inactivated seasonal
influenza vaccine is available for a child aged 5-8 years who has a medical condition that increases their risk for
influenza complications,
Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of
Afluria use before administering this
vaccine to children aged 5-8 years.